Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer

• Published in: Cancer cell international Vol. 24; no. 1; pp. 225 - 16
• Main Authors: Zhang, Xi, Chen, Rui, Huo, Zirong, Li, Wenqing, Jiang, Mengju, Su, Guodong, Liu, Yuru, Cai, Yu, Huang, Wuhao, Xiong, Yuyan, Wang, Shengguang
• Format: Journal Article
• Language: English
• Published: England BioMed Central 29.06.2024; BMC
• Subjects: Anti-PD-1 blockade; Biomarkers; Cancer therapies; CD4 antigen; Chemotherapy; Early therapy response; Gene expression; Genetic testing; Germline mutations; Hypotheses; Immune cell subsets; Immunological memory; Immunotherapy; Ligands; Lung cancer; Lymphocytes; Lymphocytes T; Memory cells; Mutation; Non-small cell lung cancer; Non-small cell lung carcinoma; Patients; PD-1 protein; PD-L1 protein; Peripheral blood; Predictive biomarker; Response rates; Small cell lung carcinoma; Transcriptomics; Tumor cell lines; Anti-PD-1 blockade; Early therapy response; Germline mutations; Immune cell subsets; Predictive biomarker; Non-small cell lung cancer

Despite the improved survival observed in PD-1/PD-L1 blockade therapy, a substantial proportion of cancer patients, including those with non-small cell lung cancer (NSCLC), still lack a response. Transcriptomic profiling was conducted on a discovery cohort comprising 100 whole blood samples, as coll...